FOR IMMEDIATE RELEASE

BioStratum Names Glenn C. Andrews Executive
VP and CFO

Research Triangle Park, N.C. -- August 9, 2000 -- BioStratum Incorporated has announced the appointment
of Glenn C. Andrews as Executive Vice President of Finance and Administration and Chief Financial Officer.

Andrews joins BioStratum with an extensive background
in financial management and business planning in
the pharmaceutical industry that includes senior level
positions with Medco Research, Inc. (acquired
by King Pharmaceuticals earlier this year), and
Burroughs Wellcome (now Glaxo Wellcome).

"Glenn has precisely the right background and
expertise to help BioStratum move to the next level",
said Dr. Claus Kühl, President and CEO of BioStratum. "His experience in financial management and strategic planning will play a key role in helping us achieve our strategic objectives as we position BioStratum to become
a publicly-traded company," Dr. Kühl added.

In his most recent position at Medco Research as Executive Vice President, Finance and Administration, Chief Financial Officer and Treasurer, Andrews played a key role in refocusing the company's strategic direction
and drug development activities. Medco Research was selected as the sixteenth best small company in America by Business Week magazine in May of 1999. Prior to that, while with Burroughs Wellcome, he was Treasurer and Director of Business Analysis and Planning and served in a number of other senior level financial positions.

BioStratum Incorporated is the world leader in basal lamina research. The basal lamina is a thin membrane that separates and directs the function of cells and tissues throughout the body, serving as the body's "biological operating system." More than two decades of research have uncovered the basal lamina's central role in degenerative diseases for which effective treatments are
not available. The company's lead drug candidate, Pyridorin™, is currently advancing through clinical trials
for diabetic kidney disease. Angiocol™, its proprietary
anti-angiogenesis agent, dramatically inhibits the growth
of tumors in animal studies, and will soon begin clinical trials. Novel therapeutic targets have also been identified
for autoimmune and kidney diseases.

In its latest round of private financing, the company raised $28 million to fund clinical trials, expand in-house drug development capabilities, and increase funding and staffing at its headquarters and its research subsidiary in Stockholm, Sweden, BioStratum AB.

###

A fact sheet on the company is available from